allogeneic-HSCT

A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%

The combination led to an overall survival rate of nearly 75% in patients with BPDCN...

Leah SherwoodAcute Myeloid Leukemia | February 1, 2023

A second allogeneic HSCT is a reasonable treatment option for patients with relapsed AML.

Leah SherwoodMyelodysplastic Syndromes | November 16, 2022

A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.

Leah SherwoodAcute Myeloid Leukemia | February 2, 2023

The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.

Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.

Cecilia BrownMyeloma | November 22, 2022

The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...

Leah SherwoodAcute Myeloid Leukemia | November 14, 2022

Mocravimod is a synthetic, sphingosine 1-phosphate receptor modulator that has been assessed in phase I and II trials.

Kerri FitzgeraldAcute Lymphoblastic Leukemia | November 16, 2022

This article discusses optimizing transplant-related care for patients with high-risk acute lymphoblastic...

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer